In order to adequately plan prevention trials, we will need to know for each region-of-interest the prevalence of tau-PET positivity—which will likely decrease with Braak stages—and the associated risk of cognitive decline—which will likely increase with Braak stages. Here, MAPT is linked to Mental deterioration.